- Home
- HOPE vs IMCR Comparison
HOPE vs IMCR Comparison
Compare HOPE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | IMCR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HOPE | IMCR |
|---|---|---|
| Price | $14.45 | $34.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $14.50 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 1.1M | 456.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 0.49 | 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $42.00 | $14.57 |
| Revenue Next Year | $19.66 | $8.21 |
| P/E Ratio | ★ $29.57 | $148.70 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $9.80 | $27.56 |
| 52 Week High | $14.50 | $40.71 |
Technical Indicators
Market Signals| Indicator | HOPE | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 54.55 |
| Support Level | $13.09 | $30.48 |
| Resistance Level | $14.48 | $35.73 |
| Average True Range (ATR) | 0.24 | 1.24 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 79.26 | 66.77 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.